Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease

Kidney International

Volumn 80, Issue 3, 2011, Pages 288-294

  Seliger, Stephen L ^a,b   Zhang, Amy D ^a   Weir, Matthew R ^a   Walker, Loreen ^c   Hsu, Van Doren ^c   Parsa, Afshin ^a   Diamantidis, Clarissa J ^a   Fink, Jeffrey C ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

cardiovascular events; chronic kidney disease; epidemiology and outcomes; epoetin

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ACUTE STROKE; AGED; ARTICLE; CANCER PATIENT; CASE CONTROL STUDY; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG USE; FEMALE; GLOMERULUS FILTRATION RATE; HEALTH CARE UTILIZATION; HEART ATRIUM FIBRILLATION; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHROLOGY; NEPHROLOGY CARE; OBSERVATIONAL STUDY; PATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE; TRANSIENT ISCHEMIC ATTACK;

EID: 79960422044     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.49     Document Type: Article

References (26)

1. Al-Ahmad A, Rand WM, Manjunath G et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001; 38: 955-962. (Pubitemid 32912694)
2. Astor BC, Coresh J, Heiss G et al. Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 2006; 151: 492-500. (Pubitemid 43144756)
3. Gerson A, Hwang W, Fiorenza J et al. Anemia and health-related quality of life in adolescents with chronic kidney disease. Am J Kidney Dis 2004; 44: 1017-1023. (Pubitemid 39556481)
4. Goicoechea M, de Vinuesa SG, Gomez-Campdera F et al. Predictive cardiovascular risk factors in patients with chronic kidney disease (CKD). Kidney Int Suppl 2005; 93: S35-S38. (Pubitemid 40019213)
5. Jurkovitz CT, Abramson JL, Vaccarino LV et al. Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based Atherosclerosis Risk in Communities (ARIC) Study. J Am Soc Nephrol 2003; 14: 2919-2925. (Pubitemid 37305654)
6. National Kidney Foundation. K/DOQI clinical practice guidelines for anemia of chronic kidney disease, 2006. Am J Kidney Dis 2006; 47(Suppl 3): S11-S145.
7. The US Recombinant Human Erythropoietin Predialysis Study Group. The US Recombinant Human Erythropoietin Predialysis Study: double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. Am J Kidney Dis 1991; 18: 50-59.
8. Leaf DE, Goldfarb DS. Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia. Kidney Int 2008; 75: 15-24.
9. Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032.
10. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098. (Pubitemid 44749317)
11. Drueke TB, Locatelli FL, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. New Engl J Med 2006; 355: 2071-2084. (Pubitemid 44749316)
12. US Food and Drug Administration. Aranesp (Darbepoetin Alfa) for Injection: Prescribing Information. US Food and Drug Administration: Silver Spring, MD, 2006: 1-21.
13. US Food and Drug Administration. Epogen (Epoetin Alfa) for Injection: Prescribing Information. US Food and Drug Administration: Silver Spring, MD, 2006: 1-30.
14. US Food and Drug Administration. Procrit (Epoetin Alfa) for Injection: Prescribing Information. US Food and Drug Administration: Silver Spring, MD, 2006: 1-21.
15. Leyland-Jones B, Semiglazov V, Pawlicki M et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. JCO 2005; 23: 1-13.
16. Bohlius J, Schmidlin K, Brillant C et al. Erythropoietin or darbepoetin for patients with cancer-meta-analysis based on individual patient data. Cochrane Database Syst Rev 2009; 3: CD007303.
17. Bohlius J, Schmidlin K, Brillant C et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009; 373: 1532-1542.
18. Tonelli M, Hemmelgarn B, Reiman T et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a metaanalysis. CMAJ 2009; 180: E62-E71.
19. Solomon SD, Uno H, Lewis EF et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010; 363: 1146-1155.
20. Frenkel EP, Bick RL, Rutherford CJ. Anemia of malignancy. Hematol Oncol Clin North Am 1996; 10: 861-873. (Pubitemid 26240363)
21. Grisold W, Oberndorfer S, Struhal W. Stroke and cancer: a review. Acta Neurol Scand 2009; 119: 1-16.
22. Agha Z, Lofgren R, Van Ruiswyk JV et al. Are patients at the Veterans Affairs medical centers sicker? A comparative analysis of health status and medical resource use. Arch Intern Med 2000; 160: 3252-3257.
23. Tirschwell DL, Longstreth WT. Validating administrative data in stroke research. Stroke 2002; 33: 2465-2470.
24. Steg PG, Lopez-Sendon J, Lopez de Sa E et al. External validity of clinical trials in acute myocardial infarction. Arch Intern Med 2007; 167: 68-73. (Pubitemid 46072409)
25. Rothwell PM. External validity of randomized controlled trials: 'to whom do the results of this trial apply?'. Lancet 2005; 365: 82.
26. Bennett CL, McKoy JM, Henke M et al. Reassessments of ESAs for cancer treatment in the US and Europe. Oncology 2010; 24: 260-268.